Transplantation after reduced intensity conditioning in patients with acute myeloid leukaemia in Sweden  by Aschan, J. et al.
93
TRANSPLANTATION AFTER REDUCED INTENSITY CONDITIONING IN
PATIENTS WITH ACUTE MYELOID LEUKAEMIA IN SWEDEN
Aschan, J.1; Ringde´n, O.1; Wahlin, A.2; Wernstedt, P.3; Brune, M.3 1.
Centre for Allogeneic Stemcell Transplantation, Karolinska University
Hospital Huddinge, Stockholm, Sweden; 2. Department of Hematology,
Norrlands University Hospital, Umeå, Sweden; 3. Department of He-
matology, Sahlgrenska University Hospital, Gothenburg, Sweden.
Thirty-seven patients, median age 58 yrs (8–69), with AML
undergoing allogeneic stem cell transplantation (SCT) after re-
duced intensity conditioning (RIC) at three Swedish SCT centers
were analyzed retrospectively. All except six patients received RIC
due to high age or co-morbidity. Twenty-three patients were
transplanted in ﬁrst remission and 14 with more advanced disease.
Donors were siblings (n22) or matched unrelated donors (MUD,
n15). Conditioning was ﬂudarabine  busulfan 	 anti-thymo-
cyte globulin (n32), ﬂudarabine  treosulfan (n3) or ﬂudara-
bine  2 Gy total body irradiation (n2). As stem cell source bone
marrow was used in six patients and peripheral blood stem cells in
31. All patients engrafted. At a median follow-up of 15 months
(3–63) acute graft-versus-host disease (GVHD) grade 0/I/II/III/IV
developed in 22/7/5/0/1 recipients, respectively. Limited chronic
GVHD was seen in ﬁve and extensive in seven patients among 33
patients at risk. Donor lymphocyte infusions were given to 16
patients due to mixed chimerism, minimal residual disease or
relapse. In total 15 patients relapsed and 12 of them died. Only one
patient died from a transplant related cause, acute GVHD. Kaplan-
Meier probability for survival at 1 yr is 79% and for leukaemia-free
survival (LFS) 68%. Among 23 patients, age 53 yrs (8–69) trans-
planted in ﬁrst remission with 16 sibling donors and seven MUD,
eight relapsed (35%) and ﬁve of them died. There was no trans-
plant-related mortality (TRM) among patients in ﬁrst remission.
Kaplan-Meier probability for survival and LFS at 1 yr is 86% and
72%, respectively for patients receiving transplantation in ﬁrst
remission. Reduced intensity conditioning with a ﬂudarabine con-
taining regimen and transplantation with a sibling or MUD gives
a low TRM even in older patients with AML. Survival is encour-
aging but leukemia relapse remains a major problem. Randomized
or controlled prospective trials comparing RIC with conventional
conditioning for younger patients and trials comparing RIC to
chemotherapy for elderly patients are urgently warranted.
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ABSENCE OF PRIOR INFECTIONS IS STRONGEST PREDICTOR FOR SUR-
VIVAL AFTER ALTERNATE DONOR HEMATOPOIETIC CELL TRANSPLAN-
TATION IN PATIENTS WITH FANCONI ANEMIA
MacMillan, M.L.1; Auerbach, A.D.2; Champagne, M.A.3; DeFor,
T.E.1; Slungaard, A.1; Weisdorf, D.J.1; Wagner, J.E.1 1. University of
Minnesota, Minneapolis, MN; 2. The Rockefeller University, New York,
NY; 3. Hopital Ste-Justine, Montreal, PQ, Canada.
Alternate donor hematopoietic cell transplantation (HCT) in
patients with Fanconi anemia (FA) has been limited by excessive
rates of graft failure (GF). In an attempt to improve results, a phase
I-II prospective trial was conducted in which ﬂudarabine (FLU,
140 mg/m2) was added to the standard regimen of cyclophospha-
mide (CY, 40 mg/kg), total body irradiation (TBI, 450 cGy) and
ATG (150 mg/kg). Between April 1999 and August 2003, 45
patients with FA (AA [n29], early MDS [n13], RAEBt/AML
[n3]) underwent T cell depleted bone marrow (BM; n38) or
umbilical cord blood transplantation (UCB; n7) from alternate
donors (HLA-mismatched related or unrelated), and were followed
for a median of 2 years (range, 1–5.3 years). Median age was 10
years (range, 1.9–33.5 years). Median BM median CD34 cells/kg
and CD3 cells/kg infused was 2.23  108 and 1  105. Median
UCB CD34 cells/kg and CD3 cells/kg infused was 3.3  105
and 1.7  106. Probability of primary neutrophil engraftment was
98% (95% CI 93–100%), a superior outcome compared to that
observed with our previous CY/TBI/ATG regimen (63% [95%
CI, 42–82%]; p
.01). Neutrophil engraftment was achieved in
15/15 patients with somatic mosaicism, a potential risk factor for
GF. Median time to neutrophil engraftment was 11 days (range,
9–35 days) in BM recipients and 14 days (range 9–36 days) in UCB
recipients. Two patients died from RRT. Probability of grade
II-IV acute GVHD was 18% (95% CI, 7–29%) and chronic
GVHD 13% (95% CI 3–23%). Probability of 1 year survival was
55% (95% CI 41–70%). In univariate analysis, high risk patient
characteristics associated with poor survival are age 18 years,
presence of RAEBt/AML, and history of major infection (fungal
infection or gram negative sepsis) prior to HCT. In multivariate
analysis, patients with a history of severe infections prior to HCT
had a 3.2 fold increased risk of mortality (95% CI 1.3–8.0; P.01).
In summary, addition of FLU to CY, TBI and ATG is associated
with superior engraftment in FA patients undergoing alternate
donor HCT. Rates of GVHD are low which may reduce the risk
of late malignancies. On the basis of these results, FLU based
preparative therapies should be considered part of the standard of
care in FA patients undergoing HCT. In addition, patients should
be transplanted earlier, before the development of serious infec-
tions.
95
INFLUENCE OF KILLER IMMUNOGLOBULIN-LIKE RECEPTOR (KIR)
MATCHING ON ACHIEVEMENT OF T-CELL (CD3) COMPLETE DONOR
CHIMERISM (CDC) IN RELATED DONOR NONMYELOABLATIVE ALLO-
GENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (NMHSCT)
Sobecks, R.; Ball, E.; Theil, K.; Brown, S., Rybicki, L.; Maciejewski, J.;
Kalaycio, M.; Pohlman, B.; Baker, J.; Bernhard, L.; Cherni, K.; Bolwell,
B. Cleveland Clinic Foundation, Cleveland, OH.
The interaction of KIRs with target cell HLA class I molecules
regulates the reactivity of NK cells and some T cell populations.
KIR interactions have been suggested to inﬂuence outcomes of
haploidentical and HLA-identical allogeneic HSCT. However, in
NMHSCT when both donor and recipient hematopoiesis may
coexist the effect of KIR interactions on outcomes is not well
known. We analyzed 31 patients undergoing related donor NMH-
SCT at our institution from 5/00–11/03. Diagnoses included 4
AML, 1 CLL, 4 CML, 2 Hodgkin’s lymphoma, 4 MDS, 2 myelo-
ﬁbrosis, 5 myeloma, 5 NHL, and 4 renal cell carcinoma. All
patients received a preparative regimen of ﬂudarabine 30 mg/m2/d
on days5,4,3, and total body irradiation 200 cGy on day1.
The median age was 51 yrs (range, 21–63 yrs). The median
CD34 and CD3 cell doses infused were 6.64  106/kg and
3.92  108/kg, respectively. CDC was deﬁned as achievement of
95% DNA of donor origin in the T-cell (CD3) enriched frac-
tions. Twenty-three (74%) of patients achieved CDC and 15
(65%) of these had a KIR mismatch, suggesting that KIR matching
per se did not correlate with CDC achievement. However, when
patient inhibitory KIR and donor ligand matches were considered
an association with CDC was observed. HLA KIR ligands were
categorized as: 1) HLA-Cw groups C1 ( or ); 2) C2 ( or );
3) HLA-Bw4 ( or ); and 4) HLA-A3 or A11 ( or ) (as
reviewed by Farag et al in Blood 100:1935, 2002). Patient KIR
genotype and donor HLA KIR ligands were used to generate an
inhibitory KIR score from 1 to 4 for the potential number of
inhibitory KIRs engaged. When the patients were analyzed 4 had
a score of 1, 16 had a score of 2, 10 had a score of 3 and 1 had a
score of 4. The Kaplan-Meier method was used to estimate the
achievement of CDC. As compared with those patients with a
score of1 the patients with a score of 1 were less likely to achieve
CDC (p0.05). Thus, patients with lower inhibitory KIR scores
may have more active anti-donor effector cells (NK cells and T cell
subsets) that may reduce donor cell chimerism. Conversely, those
with higher inhibitory KIR scores may have less active populations
and be more likely to achieve CDC. However, further investiga-
tion of larger patient populations is clearly warranted.
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REGIMEN RELATED TOXICITY AFTER THIOTEPA, CYCLOPHOSPHAMIDE
AND INTRAVENOUS BUSULFAN AS CONDITIONING FOR ALLOGENEIC
STEM CELL TRANSPLANTATION
Sanz, J.; Sanz, G.F.; Moscardo´, F.; Cupelli, L.; Montesinos, P.; Puig,
N.; Lorenzo, I.; Benlloch, L.; Jarque, I.; de la Rubia, J.; Martı´nez, J.;
Martı´n, G.; Sanz, M.A. Hospital Universitario La Fe, Valencia, Spain.
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